Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy. Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects. Here we designed two indomethacin analogues by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings. Both compounds were found to target AKR1C3 in a selective manner. In particular, hydroxyfurazan derivative is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes. High-resolution crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors. In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogues showed higher potency than indomethacin. Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3
Lolli, Marco L
First
;Carnovale, Irene M;Pippione, Agnese C;Bonanni, Davide;Marini, Elisabetta;Zonari, Daniele;Gallicchio, Margherita;Boscaro, Valentina;Rolando, Barbara;Adinolfi, Salvatore;Oliaro-Bosso, Simonetta
Co-last
;Boschi, Donatella
Co-last
2019-01-01
Abstract
Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy. Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects. Here we designed two indomethacin analogues by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings. Both compounds were found to target AKR1C3 in a selective manner. In particular, hydroxyfurazan derivative is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes. High-resolution crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors. In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogues showed higher potency than indomethacin. Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.File | Dimensione | Formato | |
---|---|---|---|
REPRINT_acsmedchemlett.8b00484.pdf
Accesso riservato
Descrizione: Articolo principale
Tipo di file:
PDF EDITORIALE
Dimensione
1.65 MB
Formato
Adobe PDF
|
1.65 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
2019-acsmedchemlett.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.65 MB
Formato
Adobe PDF
|
1.65 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Lolli et al_AKR1C3_REVISED _submitted.pdf
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
600.9 kB
Formato
Adobe PDF
|
600.9 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.